Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

Karen Lutrick; Patrick Rivers; Young M. Yoo; Lauren Grant; James Hollister; Krystal Jovel; Sana Khan; Ashley Lowe; Zoe Baccam; Hanna Hanson; Lauren E.W. Olsho; Ashley Fowlkes; Alberto J. Caban-Martinez; Cynthia Porter; Sarang Yoon; Jennifer Meece; Manjusha Gaglani; Joy Burns; Julie Mayo Lamberte; Flavia Nakayima Miiro; Adam Bissonnette; Lindsay LeClair; Preeta K. Kutty; James K. Romine; Elisha Stefanski; Laura J. Edwards; Katherine Ellingson; Joe K Gerald; Edward J. Bedrick; Purnima Madhivanan; Karl Krupp; Lynn B Gerald; Mark Thompson; Jefferey L. Burgess

doi:10.15585/MMWR.MM705152A2

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

Karen Lutrick
, Patrick Rivers
, Young M. Yoo
, Lauren Grant
, James Hollister
, Krystal Jovel
, Sana Khan
, Ashley Lowe
, Zoe Baccam
, Hanna Hanson
, Lauren E.W. Olsho
, Ashley Fowlkes
, Alberto J. Caban-Martinez
, Cynthia Porter
, Sarang Yoon
, Jennifer Meece
, Manjusha Gaglani
, Joy Burns
, Julie Mayo Lamberte
, Flavia Nakayima Miiro

Adam Bissonnette, Lindsay LeClair, Preeta K. Kutty, James K. Romine, Elisha Stefanski, Laura J. Edwards, Katherine Ellingson, Joe K Gerald, Edward J. Bedrick, Purnima Madhivanan, Karl Krupp, Lynn B Gerald, Mark Thompson, Jefferey L. Burgess

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.

Original language	English (US)
Pages (from-to)	1761-1765
Number of pages	5
Journal	Morbidity and Mortality Weekly Report
Volume	70
Issue number	5152
DOIs	https://doi.org/10.15585/MMWR.MM705152A2
State	Published - 2021

ASJC Scopus subject areas

Epidemiology
Health(social science)
Health Information Management
Health, Toxicology and Mutagenesis

Access to Document

10.15585/MMWR.MM705152A2

Cite this

Lutrick, K., Rivers, P., Yoo, Y. M., Grant, L., Hollister, J., Jovel, K., Khan, S., Lowe, A., Baccam, Z., Hanson, H., Olsho, L. E. W., Fowlkes, A., Caban-Martinez, A. J., Porter, C., Yoon, S., Meece, J., Gaglani, M., Burns, J., Lamberte, J. M., ... Burgess, J. L. (2021). Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021. Morbidity and Mortality Weekly Report, 70(5152), 1761-1765. https://doi.org/10.15585/MMWR.MM705152A2

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021. / Lutrick, Karen; Rivers, Patrick; Yoo, Young M. et al.
In: Morbidity and Mortality Weekly Report, Vol. 70, No. 5152, 2021, p. 1761-1765.

Research output: Contribution to journal › Article › peer-review

Lutrick, K, Rivers, P, Yoo, YM, Grant, L, Hollister, J, Jovel, K, Khan, S, Lowe, A, Baccam, Z, Hanson, H, Olsho, LEW, Fowlkes, A, Caban-Martinez, AJ, Porter, C, Yoon, S, Meece, J, Gaglani, M, Burns, J, Lamberte, JM, Miiro, FN, Bissonnette, A, LeClair, L, Kutty, PK, Romine, JK, Stefanski, E, Edwards, LJ, Ellingson, K, Gerald, JK, Bedrick, EJ , Madhivanan, P, Krupp, K, Gerald, LB, Thompson, M & Burgess, JL 2021, 'Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021', Morbidity and Mortality Weekly Report, vol. 70, no. 5152, pp. 1761-1765. https://doi.org/10.15585/MMWR.MM705152A2

@article{0881643b30b44671a5bc98dd72146c28,

title = "Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021",

abstract = "What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92\% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.",

author = "Karen Lutrick and Patrick Rivers and Yoo, \{Young M.\} and Lauren Grant and James Hollister and Krystal Jovel and Sana Khan and Ashley Lowe and Zoe Baccam and Hanna Hanson and Olsho, \{Lauren E.W.\} and Ashley Fowlkes and Caban-Martinez, \{Alberto J.\} and Cynthia Porter and Sarang Yoon and Jennifer Meece and Manjusha Gaglani and Joy Burns and Lamberte, \{Julie Mayo\} and Miiro, \{Flavia Nakayima\} and Adam Bissonnette and Lindsay LeClair and Kutty, \{Preeta K.\} and Romine, \{James K.\} and Elisha Stefanski and Edwards, \{Laura J.\} and Katherine Ellingson and Gerald, \{Joe K\} and Bedrick, \{Edward J.\} and Purnima Madhivanan and Karl Krupp and Gerald, \{Lynn B\} and Mark Thompson and Burgess, \{Jefferey L.\}",

year = "2021",

doi = "10.15585/MMWR.MM705152A2",

language = "English (US)",

volume = "70",

pages = "1761--1765",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "5152",

}

TY - JOUR

T1 - Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

AU - Lutrick, Karen

AU - Rivers, Patrick

AU - Yoo, Young M.

AU - Grant, Lauren

AU - Hollister, James

AU - Jovel, Krystal

AU - Khan, Sana

AU - Lowe, Ashley

AU - Baccam, Zoe

AU - Hanson, Hanna

AU - Olsho, Lauren E.W.

AU - Fowlkes, Ashley

AU - Caban-Martinez, Alberto J.

AU - Porter, Cynthia

AU - Yoon, Sarang

AU - Meece, Jennifer

AU - Gaglani, Manjusha

AU - Burns, Joy

AU - Lamberte, Julie Mayo

AU - Miiro, Flavia Nakayima

AU - Bissonnette, Adam

AU - LeClair, Lindsay

AU - Kutty, Preeta K.

AU - Romine, James K.

AU - Stefanski, Elisha

AU - Edwards, Laura J.

AU - Ellingson, Katherine

AU - Gerald, Joe K

AU - Bedrick, Edward J.

AU - Madhivanan, Purnima

AU - Krupp, Karl

AU - Gerald, Lynn B

AU - Thompson, Mark

AU - Burgess, Jefferey L.

PY - 2021

Y1 - 2021

N2 - What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.

AB - What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.

UR - https://www.scopus.com/pages/publications/85123036935

UR - https://www.scopus.com/pages/publications/85123036935#tab=citedBy

U2 - 10.15585/MMWR.MM705152A2

DO - 10.15585/MMWR.MM705152A2

M3 - Article

C2 - 34968373

AN - SCOPUS:85123036935

SN - 0149-2195

VL - 70

SP - 1761

EP - 1765

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 5152

ER -

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this